Search Results

Launched in 2024, Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells.

At ReproNovo, we are redefining what’s possible in reproductive medicine and women’s health.

We are dedicated to providing a new dawn or “eos” for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need.

Our mission is to create a future where patients with neurological diseases are effectively treated.

Light Horse is leading the way in precision genome editing applied to small molecule drug discovery, pioneering approaches to target the root causes of disabling and life-threatening diseases.

Leyden Labs aims to help people live their lives to the fullest. Our platform targets commonalities of viral families to protect humanity from known and future viruses. Our portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many variants of respiratory viruses, including ones in the influenza and coronavirus families.

As a company focused on rapidly advancing next generation transformative assets, we leverage our expertise to efficiently progress programs to clinical proof of concept.